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In many developing nations where primary percutaneous coronary intervention (PPCI) is 
not widely available, ST-segment elevation myocardial infarction (STEMI) patients are still 
treated by thrombolysis (1). However, as thrombolytic therapy is less effective than PPCI at 
restoring blood flow in the infarct-related coronary artery, thrombolyzed STEMI patients 
experience larger myocardial infarcts and are more likely to develop heart failure. As such, there 
is an urgent need for an innovative, easily applied, and low-cost cardioprotective therapy. In this 
regard, the heart can be protected against MI, by simply applying cycles of brief 
ischemia/reperfusion to the arm or leg–a phenomenon termed remote ischemic conditioning 
(RIC) (2). Therefore, we hypothesized that RIC initiated on arrival at the hospital and prior to 
thrombolysis can reduce enzymatic MI size in STEMI patients (the ERIC-LYSIS Study: 
NCT02197117).  
We performed a multicenter single-blinded, randomized controlled trial in the developing 
nation of Mauritius. The Mauritian Ministry of Health and Quality of Life provided ethical 
approval of the study. All patients gave informed consent before entering the study. Adult 
patients presenting with a STEMI were randomly assigned to receive either RIC (4 5-minutes 
cycles of upper-arm cuff inflation to 200 mmHg and deflation) or control (un-inflated cuff placed 
on the upper-arm for 40 minutes) on immediate arrival at the hospital. Exclusion criteria 
included contra-indications for thrombolysis; previous MI; cardiac arrest; arterio-venous shunts; 
and pre-existing treatment with nicorandil or glibenclamide. Thrombolysis was achieved using 
streptokinase at a dose of 1.5 million units over 60 minutes. The RIC or control protocols were 
initiated prior to and continued during thrombolysis, and did not delay the onset of reperfusion. 
The predefined primary endpoint was enzymatic MI size assessed by 24 hour area-under-the-
curve (AUC) serum Troponin-T and CK-MB, measured at 0, 6, 12, and 24 hours. 
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Between March 2011 and November 2013, 519 STEMI patients were randomly assigned 
to receive either RIC (N = 258) or control (N = 261). The 2 groups were similar in patient 
characteristics. Data were available for 414 patients for AUC Troponin-T and 407 patients for 
AUC CK-MB. Median enzymatic MI size was 32% (24 hr AUC Troponin-T) and 19% (24 hr 
AUC CK-MB) smaller in patients administered RIC when compared to control patients (Table) 
The ERIC-LYSIS study was the first to investigate the effect of RIC in STEMI patients 
reperfused by thrombolysis in a developing nation. We found that those patients randomized to 
receive RIC upon arrival at the hospital and prior to thrombolytic therapy experienced a 
significant reduction in enzymatic MI size when compared to control. The size of this 
cardioprotective effect is comparable to that observed in STEMI patients treated by PPCI, in 
which studies have reported 25-30% reductions in MI size measured by myocardial SPECT and 
cardiac MRI (3-5). The limitations of our study include the following: although tissue 
plasminogen activator (t-PA) is the most commonly used thrombolytic agent in developed 
countries, streptokinase (which costs 10-fold less than t-PA) continues to be used in developing 
nations; and conducting a randomized control trial in a developing nation with very limited 
resources was challenging and explains in part why we were only able to obtain data on 
enzymatic MI size. 
In conclusion, we have shown that RIC reduced MI size in STEMI patients treated with 
thrombolysis, making this noninvasive, easily applied, low cost therapy an attractive option in 
developing nations where health care resources are limited and current therapy is not optimal.     
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Table 1: Patient characteristics and AUC cardiac enzymes 
Variable Control (N=258) RIC (N=261) 
 
P-value   
Male 204 (79%) 209 (80%)  
Age (years) 56 ± 11 57 ± 11  
Enzymatic MI 
size (ng.h/ml) 
 
24 hr AUC CK-
MB 
Mean ± SD  
Median (IQR) 
 
24 hr AUC 
Troponin-T 
Mean ± SD  
Median (IQR) 
 
 
 
 
 
 
2,894 ± 2,306 
2,381 (980, 4,690) 
 
 
105.9 ± 69.5 
109.0 (41.1, 162.7) 
 
 
 
 
 
2,378 ± 2,089 
1,928 (780, 3,289) 
 
 
90.0 ± 67.6 
74.6 (28.5, 149.0) 
 
 
 
 
 
0.026 
 
 
 
0.020 
 
 
Values are expressed as number (%) and mean ± SD. SD, standard deviation; AUC, area under 
the curve. CI, confidence interval; IQR, inter-quartile range. *p-value from non-parametric 
Mann-Whitney U test for equality of distributions between control and RIC arms. 
